Renaissance Technologies LLC Has $422,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Renaissance Technologies LLC grew its position in Century Therapeutics, Inc. (NASDAQ:IPSC) by 6.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 165,500 shares of the company’s stock after purchasing an additional 9,500 shares during the period. Renaissance Technologies LLC owned about 0.20% of Century Therapeutics worth $422,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IPSC. Abel Hall LLC bought a new position in Century Therapeutics during the fourth quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Century Therapeutics in the first quarter valued at approximately $47,000. Vanguard Group Inc. raised its holdings in shares of Century Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock worth $4,760,000 after acquiring an additional 14,000 shares during the period. Rhumbline Advisers lifted its position in Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after acquiring an additional 18,828 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Century Therapeutics by 141.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares during the period. 50.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. HC Wainwright decreased their price objective on Century Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Rodman & Renshaw started coverage on shares of Century Therapeutics in a research note on Thursday, August 8th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, Piper Sandler increased their price target on Century Therapeutics from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Monday, June 17th.

Century Therapeutics Stock Down 0.7 %

Century Therapeutics stock opened at $1.39 on Friday. Century Therapeutics, Inc. has a 12-month low of $1.28 and a 12-month high of $5.51. The business’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $2.55. The stock has a market cap of $117.46 million, a PE ratio of -0.63 and a beta of 1.36.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.12. The company had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.55 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. As a group, analysts expect that Century Therapeutics, Inc. will post -1.8 earnings per share for the current year.

Century Therapeutics Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.